BridgeBio Pharma (NASDAQ:BBIO) Director Sells 2,196 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Hannah Valantine sold 2,196 shares of the stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $68.57, for a total transaction of $150,579.72. Following the completion of the transaction, the director directly owned 9,259 shares in the company, valued at $634,889.63. This trade represents a 19.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hannah Valantine also recently made the following trade(s):

• On Monday, June 22nd, Hannah Valantine sold 2,808 shares of BridgeBio Pharma stock. The shares were sold at an average price of $68.00, for a total transaction of $190,944.00.

BridgeBio Pharma Stock Performance

NASDAQ BBIO traded up $0.63 during trading hours on Wednesday, hitting $69.26. The company had a trading volume of 4,190,473 shares, compared to its average volume of 2,788,713. The business has a 50 day moving average of $69.37 and a 200-day moving average of $71.90. The company has a market cap of $13.56 billion, a PE ratio of -18.52 and a beta of 0.97. BridgeBio Pharma, Inc. has a 1-year low of $41.80 and a 1-year high of $84.94.

BridgeBio Pharma (NASDAQ:BBIO) last posted its earnings results on Thursday, May 7th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.14). The firm had revenue of $194.51 million during the quarter, compared to analyst estimates of $178.07 million. During the same quarter in the prior year, the business earned ($0.88) EPS. The business’s quarterly revenue was up 66.8% on a year-over-year basis. Sell-side analysts expect that BridgeBio Pharma, Inc. will post -2.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BridgeBio Pharma

Several large investors have recently modified their holdings of BBIO. Commonwealth Equity Services LLC raised its stake in shares of BridgeBio Pharma by 4.9% during the fourth quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company’s stock worth $396,000 after purchasing an additional 244 shares during the last quarter. Farther Finance Advisors LLC grew its position in BridgeBio Pharma by 91.4% in the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock valued at $39,000 after buying an additional 245 shares during the last quarter. State of New Jersey Common Pension Fund D increased its stake in BridgeBio Pharma by 0.5% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 51,896 shares of the company’s stock valued at $3,970,000 after buying an additional 246 shares during the period. CWM LLC increased its stake in BridgeBio Pharma by 4.3% in the 4th quarter. CWM LLC now owns 6,444 shares of the company’s stock valued at $493,000 after buying an additional 265 shares during the period. Finally, Xponance LLC raised its position in BridgeBio Pharma by 2.2% during the 4th quarter. Xponance LLC now owns 12,536 shares of the company’s stock worth $959,000 after buying an additional 272 shares during the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BBIO. Barclays restated an “overweight” rating on shares of BridgeBio Pharma in a research report on Tuesday, March 10th. JPMorgan Chase & Co. increased their price target on shares of BridgeBio Pharma from $89.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 10th. Raymond James Financial downgraded shares of BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 26th. Oppenheimer dropped their price objective on shares of BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 25th. Finally, HC Wainwright reiterated a “buy” rating and set a $110.00 target price on shares of BridgeBio Pharma in a research note on Thursday, May 28th. Twenty-two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $91.05.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.